JP2023539246A - 腫瘍微小環境の遺伝的調節のための方法及び組成物 - Google Patents

腫瘍微小環境の遺伝的調節のための方法及び組成物 Download PDF

Info

Publication number
JP2023539246A
JP2023539246A JP2023513297A JP2023513297A JP2023539246A JP 2023539246 A JP2023539246 A JP 2023539246A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023539246 A JP2023539246 A JP 2023539246A
Authority
JP
Japan
Prior art keywords
group
cancer
inhibitor
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539246A5 (cg-RX-API-DMAC7.html
Inventor
ピー. ビソネット,レイド
エム. シーザリオ,ローズマリー
グデノフ,ロバート
ショジャエイ,ファーボッド
ギリングス,ミレイユ
Original Assignee
フヤバイオ インターナショナル,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル,エルエルシー filed Critical フヤバイオ インターナショナル,エルエルシー
Publication of JP2023539246A publication Critical patent/JP2023539246A/ja
Publication of JP2023539246A5 publication Critical patent/JP2023539246A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023513297A 2020-08-25 2021-08-24 腫瘍微小環境の遺伝的調節のための方法及び組成物 Pending JP2023539246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070173P 2020-08-25 2020-08-25
US63/070,173 2020-08-25
PCT/US2021/047380 WO2022046792A2 (en) 2020-08-25 2021-08-24 Methods and compositions for genetic modulation of tumor microenvironments

Publications (2)

Publication Number Publication Date
JP2023539246A true JP2023539246A (ja) 2023-09-13
JP2023539246A5 JP2023539246A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80355668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513297A Pending JP2023539246A (ja) 2020-08-25 2021-08-24 腫瘍微小環境の遺伝的調節のための方法及び組成物

Country Status (10)

Country Link
US (1) US20220110924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539246A (cg-RX-API-DMAC7.html)
KR (1) KR20230057426A (cg-RX-API-DMAC7.html)
AU (1) AU2021333655A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190514A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002286A (cg-RX-API-DMAC7.html)
WO (1) WO2022046792A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654979A1 (en) * 2023-01-25 2025-12-03 Huyabio International, LLC Methods and compositions comprising a cardio-tolerated hdac inhibitor
CN117357530A (zh) * 2023-11-07 2024-01-09 苏州大学附属儿童医院 Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519498A (ja) * 2016-05-11 2019-07-11 フヤ バイオサイエンス インターナショナル エルエルシー Hdac阻害剤とpd−1阻害剤との組み合わせ療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519498A (ja) * 2016-05-11 2019-07-11 フヤ バイオサイエンス インターナショナル エルエルシー Hdac阻害剤とpd−1阻害剤との組み合わせ療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A Phase 1b/2 Study of the Safety and Efficacy of HBI-8000-Nivolumab Combination in Melanoma (MEL), R", SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC), JPN6025040905, 2018, ISSN: 0005846205 *
CANCER CHEMOTHER PHARMACOL, vol. 69, JPN6025040904, 2012, pages 1413 - 1422, ISSN: 0005846206 *

Also Published As

Publication number Publication date
EP4203955A2 (en) 2023-07-05
CA3190514A1 (en) 2022-03-03
KR20230057426A (ko) 2023-04-28
AU2021333655A9 (en) 2024-06-06
ZA202302154B (en) 2023-10-25
AU2021333655A1 (en) 2023-05-04
EP4203955A4 (en) 2024-09-18
US20220110924A1 (en) 2022-04-14
WO2022046792A3 (en) 2022-04-07
MX2023002286A (es) 2023-05-16
BR112023003466A2 (pt) 2023-05-09
WO2022046792A2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7190548B2 (ja) Hdac阻害剤とpd-l1阻害剤との組み合わせ療法
US20250026832A1 (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
US20220110924A1 (en) Methods and compositions for genetic modulation of tumor microenvironments
US20200383961A1 (en) Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors
WO2024015478A2 (en) Combination therapies of wdr5 inhibitors and pd-1 inhibitors
JP2026503609A (ja) 心臓耐容性hdac阻害剤を含む方法および組成物
HK40129132A (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2025090881A1 (en) Combination therapies of wdr5 inhibitors and pd-1 inhibitors
EA045229B1 (ru) Комбинация ингибиторов hdac и pd-1 и её применение для лечения рака толстой кишки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260422